 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does HALOPERIDOL increase or decrease the risk of bleeding?
 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT 
*(orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does HALOPERIDOL increase or decrease the risk of bleeding?"
  }
}
*(orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does HALOPERIDOL increase or decrease the risk of bleeding?
 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does HALOPERIDOL increase or decrease the risk of bleeding?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_extracts) FUNC: {
  "name": "relevant_extracts",
  "to": "",
  "arguments": {
    "query": "Does HALOPERIDOL increase or decrease the risk of bleeding?",
    "filter_drugs": [
      "HALOPERIDOL"
    ]
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_extracts) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: HALOPERIDOL: warnings: WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are 
at an increased risk of death. Haloperidol is not approved for the treatment of patients with dementia-related psychosis (see BOXED WARNING ). Cardiovascular Effects Cases of sudden death, 
QT-prolongation, and Torsades de pointes have been reported in patients receiving haloperidol. Higher than recommended doses of any formulation of haloperidol appear to be associated with a higher 
risk of QT-prolongation and Torsades de pointes. Although cases have been reported even in the absence of predisposing factors, particular caution is advised in treating patients with other 
QT-prolonging conditions (including electrolyte imbalance , drugs known to prolong QT, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome). HALOPERIDOL: warnings: Tardive 
Dyskinesia A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome 
appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely
to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. Both the risk of developing tardive dyskinesia and the likelihood that it
will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can 
develop, although much less commonly, after relatively brief treatment periods at low doses. HALOPERIDOL: warnings: There is no known treatment for established cases of tardive dyskinesia, although 
the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the 
syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, 
antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who
suffer from a chronic illness that, 1) is known to respond to antipsychotic drugs, and, 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or 
appropriate. HALOPERIDOL: warnings: In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. 
The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. 
However, some patients may require treatment despite the presence of the syndrome. (For further information about the description of tardive dyskinesia and its clinical detection, please refer to 
ADVERSE REACTIONS .) Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with 
antipsychotic drugs.         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: warnings: Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular 
pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure. The 
diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness
(e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central 
anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. HALOPERIDOL: warnings: The management of NMS should include 1) immediate discontinuation of 
antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for 
which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after
recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Hyperpyrexia and
heat stroke, not associated with the above symptom complex, have also been reported with haloperidol. Falls Haloperidol tablets, USP may cause somnolence, postural hypotension, motor and sensory 
instability, which may lead to falls and, consequently, fractures or other injuries. HALOPERIDOL: warnings: For patients with diseases, conditions, or medications that could exacerbate these effects, 
complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. Usage in Pregnancy Pregnancy Nonteratogenic Effects Neonates 
exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, 
hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other 
cases neonates have required intensive care unit support and prolonged hospitalization. Haloperidol should be used during pregnancy only if the potential benefit justifies the potential risk to the 
fetus. HALOPERIDOL: warnings: Rodents given 2 to 20 times the usual maximum human dose of haloperidol by oral or parenteral routes showed an increase in incidence of resorption, reduced fertility, 
delayed delivery and pup mortality. No teratogenic effect has been reported in rats, rabbits or dogs at dosages within this range, but cleft palate has been observed in mice given 15 times the usual 
maximum human dose. Cleft palate in mice appears to be a nonspecific response to stress or nutritional imbalance as well as to a variety of drugs, and there is no evidence to relate this phenomenon to
predictable human risk for most of these agents. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb malformations observed following 
maternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. 
HALOPERIDOL: warnings: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women likely to become pregnant only 
if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Combined Use of Haloperidol and Lithium An encephalopathic syndrome (characterized 
by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few 
patients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients 
receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear. HALOPERIDOL: general_precautions: 
General A number of cases of bronchopneumonia, some fatal, have followed the use of antipsychotic drugs, including haloperidol. It has been postulated that lethargy and decreased sensation of thirst 
due to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation. Therefore, if the above signs and symptoms appear, especially in the elderly, the physician 
should institute remedial therapy promptly. Although not reported with haloperidol, decreased serum cholesterol and/or cutaneous and ocular changes have been reported in patients receiving 
chemically-related drugs. Haloperidol may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. The 
ambulatory patient should be warned accordingly. The use of alcohol with this drug should be avoided due to possible additive effects and hypotension.         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: adverse_reactions: It is not known whether gradual withdrawal of antipsychotic drugs will reduce the rate of occurrence of withdrawal emergent neurological signs but until 
further evidence becomes available, it seems reasonable to gradually withdraw use of haloperidol. Tardive Dyskinesia As with all antipsychotic agents, haloperidol has been associated with persistent 
dyskinesias. Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may appear in some patients on long-term therapy or may occur after drug therapy 
has been discontinued. The risk appears to be greater in elderly patients on high dose therapy, especially females. The symptoms are persistent and in some patients appear irreversible. The syndrome 
is characterized by rhythmical involuntary movements of tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be 
accompanied by involuntary movements of extremities and the trunk. HALOPERIDOL: adverse_reactions: There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not 
alleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage
of the agent, or switch to a different antipsychotic agent, this syndrome may be masked. It has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and
if the medication is stopped at that time, the full syndrome may not develop. Tardive Dystonia Tardive dystonia, not associated with the above syndrome, has also been reported. Tardive dystonia is 
characterized by delayed onset of choreic or dystonic movements, is often persistent, and has the potential of becoming irreversible. HALOPERIDOL: adverse_reactions: Other CNS Effects Insomnia, 
restlessness, anxiety, euphoria, agitation, drowsiness, depression, lethargy, headache, confusion, vertigo, grand mal seizures, exacerbation of psychotic symptoms including hallucinations and 
catatonic-like behavioral states which may be responsive to drug withdrawal and/or treatment with anticholinergic drugs. Body as a Whole: Neuroleptic malignant syndrome (NMS), hyperpyrexia and heat 
stroke have been reported with haloperidol. (See WARNINGS for further information concerning NMS.) Hematologic Effects: Reports have appeared citing the occurrence of mild and usually transient 
leukopenia and leukocytosis, minimal decreases in red blood cell counts, anemia, or a tendency toward lymphomonocytosis. Agranulocytosis has rarely been reported to have occurred with the use of 
haloperidol, and then only in association with other medication. HALOPERIDOL: adverse_reactions: Liver Effects: Impaired liver function and/or jaundice have been reported. Dermatologic Reactions: 
Maculopapular and acneiform skin reactions and isolated cases of photosensitivity and loss of hair. Endocrine Disorders: Lactation, breast engorgement, mastalgia, menstrual irregularities, 
gynecomastia, impotence, increased libido, hyperglycemia, hypoglycemia and hyponatremia. Gastrointestinal Effects: Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting. 
Autonomic Reactions: Dry mouth, blurred vision, urinary retention, diaphoresis and priapism. Respiratory Effects: Laryngospasm, bronchospasm and increased depth of respiration. Special Senses: 
Cataracts, retinopathy and visual disturbances. HALOPERIDOL: adverse_reactions: Post-marketing Events Hyperammonemia has been reported in a 5-1‚ÅÑ2 year old child with citrullinemia, an inherited 
disorder of ammonia excretion, following treatment with haloperidol.         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs 
are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in 
drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was 
about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death)
or infectious (e.g., pneumonia) in nature. HALOPERIDOL: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may 
increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is
not clear. Haloperidol is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS ).         
SOURCE:HALOPERIDOL label


CONTENT: HALOPERIDOL: precautions: PRECAUTIONS Leukopenia, Neutropenia and Agranulocytosis In clinical trial and post-marketing experience, events of leukopenia/neutropenia have been reported 
temporally related to antipsychotic agents, including haloperidol. Agranulocytosis (including fatal cases) has also been reported. Possible risk factors for leukopenia/neutropenia include preexisting 
low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a preexisting low WBC or a history of drug induced leukopenia/neutropenia should have their complete 
blood count (CBC) monitored frequently during the first few months of therapy and should discontinue haloperidol at the first sign of a decline in WBC in the absence of other causative factors. 
HALOPERIDOL: precautions: Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with 
severe neutropenia (absolute neutrophil count < 1,000/mm 3 ) should discontinue haloperidol and have their WBC followed until recovery. Haloperidol should be administered cautiously to patients: -with
severe cardiovascular disorders, because of the possibility of transient hypotension and/or precipitation of anginal pain. Should hypotension occur and a vasopressor be required, epinephrine should 
not be used since haloperidol may block its vasopressor activity and paradoxical further lowering of the blood pressure may occur. Instead, metaraminol, phenylephrine or norepinephrine should be used.
-receiving anticonvulsant medications, with a history of seizures, or with EEG abnormalities, because haloperidol may lower the convulsive threshold. HALOPERIDOL: precautions: If indicated, adequate 
anticonvulsant therapy should be concomitantly maintained. -with known allergies, or with a history of allergic reactions to drugs. -receiving anticoagulants, since an isolated instance of 
interference occurred with the effects of one anticoagulant (phenindione). If concomitant antiparkinson medication is required, it may have to be continued after haloperidol is discontinued because of
the difference in excretion rates. If both are discontinued simultaneously, extrapyramidal symptoms may occur. The physician should keep in mind the possible increase in intraocular pressure when 
anticholinergic drugs, including antiparkinson agents, are administered concomitantly with haloperidol. As with other antipsychotic agents, it should be noted that haloperidol may be capable of 
potentiating CNS depressants such as anesthetics, opiates, and alcohol. HALOPERIDOL: precautions: In a study of 12 schizophrenic patients coadministered haloperidol and rifampin, plasma haloperidol 
levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline. In five other schizophrenic patients treated with haloperidol and rifampin, 
discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations. Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in 
haloperidol-treated patients. When haloperidol is used to control mania in cyclic disorders, there may be a rapid mood swing to depression. Severe neurotoxicity (rigidity, inability to walk or talk) 
may occur in patients with thyrotoxicosis who are also receiving antipsychotic medication, including haloperidol. HALOPERIDOL: precautions: No mutagenic potential of haloperidol was found in the Ames 
Salmonella microsomal activation assay. Negative or inconsistent positive findings have been obtained in in vitro and in vivo studies of effects of haloperidol on chromosome structure and number. The 
available cytogenetic evidence is considered too inconsistent to be conclusive at this time. Carcinogenicity studies using oral haloperidol were conducted in Wistar rats (dosed at up to 5 mg/kg daily 
for 24 months) and in Albino Swiss mice (dosed at up to 5 mg/kg daily for 18 months). In the rat study, survival was less than optimal in all dose groups, reducing the number of rats at risk for 
developing tumors. However, although a relatively greater number of rats survived to the end of the study in high dose male and female groups, these animals did not have a greater incidence of tumors 
than control animals. HALOPERIDOL: precautions: Therefore, although not optimal, this study does suggest the absence of a haloperidol related increase in the incidence of neoplasia in rats at doses up
to 20 times the usual daily human dose for chronic or resistant patients. In female mice at 5 and 20 times the highest initial daily dose for chronic or resistant patients, there was a statistically 
significant increase in mammary gland neoplasia and total tumor incidence; at 20 times the same daily dose there was a statistically significant increase in pituitary gland neoplasia. In male mice, no
statistically significant differences in incidences of total tumors or specific tumor types were noted. Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic 
administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these
drugs is contemplated in a patient with a previously detected breast cancer. HALOPERIDOL: precautions: Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been 
reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of 
antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; 
the available evidence is considered too limited to be conclusive at this time. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb 
malformations observed following maternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not 
established in these cases. HALOPERIDOL: precautions: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women 
likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Pediatric Use Safety and effectiveness in pediatric 
patients have not been established. Geriatric Use Clinical studies of haloperidol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from 
younger subjects. Other reported clinical experience has not consistently identified differences in responses between the elderly and younger patients. However, the prevalence of tardive dyskinesia 
appears to be highest among the elderly, especially elderly women (see WARNINGS: Tardive Dyskinesia ). Also, the pharmacokinetics of haloperidol in geriatric patients generally warrants the use of 
lower doses (see DOSAGE AND ADMINISTRATION ).         
SOURCE:HALOPERIDOL label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          )  DO-NOT-KNOW
*(FDAHandler)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does HALOPERIDOL increase or decrease the risk of bleeding?",
    "drug": "HALOPERIDOL"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does HALOPERIDOL increase or decrease the risk of 
bleeding?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-bleeding-HALOPERIDOL)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-bleeding-HALOPERIDOL)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-bleeding-HALOPERIDOL)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT 
*(orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does HALOPERIDOL increase or decrease the risk of bleeding?",
    "steps": [
      "I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of bleeding."
    ],
    "answer": "DO-NOT-KNOW"
  }
}
*(orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) __PASS__:Critic
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(Entity.LLM) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  FDAHandler  Entity.USER(FDAHandler) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (Critic)  Entity.USER  Entity.USER(          ) (=>    Critic) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does HALOPERIDOL increase or decrease the risk of bleeding?",
    "steps": [
      "I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of bleeding."
    ],
    "answer": "DO-NOT-KNOW",
    "request": "final_answer"
  }
}
*(Critic)  Entity.AGENT  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) 
        Question: Does HALOPERIDOL increase or decrease the risk of bleeding?
        -----
        Reasoning:
        1. I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of bleeding.
        -----
        Final answer: DO-NOT-KNOW
        
 (Critic)  Entity.USER 
 (Critic)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(Critic)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "The final answer lacks the necessary explanation for why it was not possible to answer the question. The user should clarify whether the DO-NOT-KNOW response is due to FDAHandler not 
having the information or if there is another reason for the inability to provide a definitive answer."
  }
}
*(Critic)  Entity.LLM  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) <DONE> __PASS__
*(orchestrator-bleeding-HALOPERIDOL)  Critic  Entity.USER(    Critic) (=>     AGENT) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "The final answer lacks the necessary explanation for why it was not possible to answer the question. The user should clarify whether the DO-NOT-KNOW response is due to FDAHandler not 
having the information or if there is another reason for the inability to provide a definitive answer.",
    "request": "feedback"
  }
}
*(orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) 
        Feedback: The final answer lacks the necessary explanation for why it was not possible to answer the question. The user should clarify whether the DO-NOT-KNOW response is due to FDAHandler not
having the information or if there is another reason for the inability to provide a definitive answer.

        If any flaws in the reasoning used to produce your
        answer were identified, you must try again.
        
 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER 
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) I apologize for the lack of clarity in my previous response. Let me clarify 
the steps I took to answer your question and why I was unable to provide a definitive answer.

To determine whether haloperidol increases or decreases the risk of bleeding, I sent a query to FDAHandler, which is the entity that can provide information based on FDA drug labels. Unfortunately, 
FDAHandler responded with a DO-NOT-KNOW, which indicates that the FDA label for haloperidol does not contain information regarding its effects on bleeding risk. This means that there is no specific 
information available in the FDA label that either confirms or denies an association between haloperidol and an increased or decreased risk of bleeding.

Given this lack of information from the FDA label, I am unable to provide a definitive answer to your question. Therefore, my final answer remains DO-NOT-KNOW, and the justification is that the FDA 
label data, as provided by FDAHandler, does not specify any information regarding the effect of haloperidol on bleeding risk.
 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER 
*(orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(          ) (=>       LLM) (X           )       (          ) 
        Do one of the following:

        1. If you intend to ask a question to FDAAgent:
            Please use the 'add_recipient' tool/function-call
            and specify FDAAgent as your `intended_recipient`.
            DO NOT REPEAT your original message; ONLY specify the 
            `intended_recipient` via this tool/function-call.
        2. If you are ready to have the critic check your answer,
            do so with the `final_answer` tool/function, as I have requested.
        3. If the critic is satisfied and you intend to submit your final answer,
            answer as I have requested, making sure to mark that you are done as usual.

        When you have decided and stated your answer (or lack of one), you must
        ALWAYS specify that you are done using the usual code.

        DO NOT simply acknowldedge these instructions. If you have nothing
        else to say, you MUST EXIT IMMEDIATELY by stating that you are done
        with the usual code (as in #3).
        
 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER  Entity.USER(Entity.USER) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does HALOPERIDOL increase or decrease the risk of bleeding?",
    "steps": [
      "I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of bleeding.",
      "FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for haloperidol does not contain information regarding its effects on bleeding risk."
    ],
    "answer": "DO-NOT-KNOW"
  }
}
*(orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) __PASS__:Critic
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(Entity.LLM) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-bleeding-HALOPERIDOL)  FDAHandler  Entity.USER(FDAHandler) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (Critic)  Entity.USER  Entity.USER(          ) (=>    Critic) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does HALOPERIDOL increase or decrease the risk of bleeding?",
    "steps": [
      "I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of bleeding.",
      "FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for haloperidol does not contain information regarding its effects on bleeding risk."
    ],
    "answer": "DO-NOT-KNOW",
    "request": "final_answer"
  }
}
*(Critic)  Entity.AGENT  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) 
        Question: Does HALOPERIDOL increase or decrease the risk of bleeding?
        -----
        Reasoning:
        1. I asked FDAHandler whether HALOPERIDOL increases or decreases the risk of bleeding.
2. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for haloperidol does not contain information regarding its effects on bleeding risk.
        -----
        Final answer: DO-NOT-KNOW
        
 (Critic)  Entity.USER 
 (Critic)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(Critic)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": ""
  }
}
*(Critic)  Entity.LLM  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) <DONE> __PASS__
*(orchestrator-bleeding-HALOPERIDOL)  Critic  Entity.USER(    Critic) (=>     AGENT) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "",
    "request": "feedback"
  }
}
*(orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) Your reasoning is valid, no feedback was provided.
 (orchestrator-bleeding-HALOPERIDOL)  Entity.USER 
 (orchestrator-bleeding-HALOPERIDOL)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-bleeding-HALOPERIDOL)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW

The question was whether haloperidol increases or decreases the risk of bleeding. I asked FDAHandler for information regarding the effects of haloperidol on bleeding risk. FDAHandler responded with 
DO-NOT-KNOW, which means that the FDA label for haloperidol does not specify any information about its impact on bleeding risk. Therefore, based on the available FDA label data, it is not possible to 
determine whether haloperidol has an effect on bleeding risk. The absence of information in the FDA label suggests that there may not be a known or established effect, or that it has not been 
sufficiently studied or reported to warrant inclusion in the label.
